… gefitinib therapy according to response to erlotinib, it was significantly longer in patients who
showed PR/SD on erlotinib than in patients who did not (279 v 111 days in patients without …

… suggested that erlotinib should not be given routinely after failure of gefitinib treatment, but
… subset of patients, especially those who had already benefited from prior gefitinib treatment. …

… gefitinib and erlotinib in an enriched patient … of gefitinib or erlotinib independently compared
to a historical control as the second-line therapy in patients with NSCLC who have failed …

… between gefitinib-treated and erlotinib-treated patients with NSCLC who had failed prior
chemotherapy. Our analysis shows that gefitinib and erlotinib in pretreated patients with …

… Erlotinib seems to be a potential therapeutic option for treatment of selected advanced NSCLC
patients after failure of gefitinib. … clarify how to select patients for treatment with epidermal …

… In our study, The DCR of erlotinib after gefitinib failure was similar to that in Cho’s study.
Most patients who benefit from erlotinib had also benefited from prior gefitinib treatment, but we …

… patients who receive erlotinib after gefitinib failure revealed that erlotinib may produce clinical
benefits in patients … than 6 months) for prior gefitinib therapy. Moreover, EGFR mutations …

… gefitinib, particularly in patients in whom the disease had been stabilized for a long time prior
to gefitinib … toxicity of gefitinib in patients whose disease progressed after erlotinib therapy. …

… In conclusion, when rechallenging with the EGFR TKI erlotinib following gefitinib failure,
patients who showed prolonged PFS with gefitinib may benefit from erlotinib treatment. Further …

… Between January 2008 and October 2009, we analyzed 125 patients with relapsed
NSCLC who had received erlotinib therapy after gefitinib failure at our institutes. Results were …